Biotechnology
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...
2026-08-24 09:54
1
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...
2026-08-21 20:08
4709
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...
2026-08-21 17:28
898
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...
2026-08-21 17:20
1127
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZE...
2026-08-21 16:03
1046
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's Nat...
2026-08-21 13:30
1367
Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants
The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigati...
2026-08-20 19:00
819
Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the g...
2026-08-19 19:46
1266
NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product
WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORRO...
2026-08-19 17:00
1006
CARsgen Therapeutics Announces 2026 Interim Results
SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights * Cash and cash equivalents were around RMB1,400 million as of June ...
2026-08-19 08:15
1850
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
* Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics develo...
2026-08-19 03:44
1278
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-08-18 17:02
1228
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody i...
2026-08-18 12:03
2513
Enginprime Medical Closes $12M Series A Financing
Round exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development SHANGHAI and HANGZHOU, China, Aug. 17, 2026 /PRNewswire/ -- Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular assist...
2026-08-18 08:00
2333
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths
CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital Internatio...
2026-08-17 20:30
3613
Kelun-Biotech Announces 2026 Interim Results
CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: * Re...
2026-08-17 19:18
3951
SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate
* Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months * Company expands its global portfolio beyond vaccines into antibody-based preventive technologies * Growing global R&D network strengthens capabilities in next-generation...
2026-08-14 20:00
3677
/DISREGARD RELEASE: IASO Bio/
We are advised by IASO Bio that journalists and other readers should disregard the news release, IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics, issued 13-Aug-2026 over PR Newswire, as the release contained erroneous information. ...
2026-08-14 13:30
3908
Mervyn's Petcare Marks One Year at Magnify Incubator on UCLA campus with Launch of Second Feline Supplement on Amazon
SEOUL, South Korea, Aug. 13, 2026 /PRNewswire/ -- Ari's Purrfect
Omega+Multivitamin Lickable Supplement
2026-08-13 21:00
2800
Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced that it will present efficacy and safety results from a Phase 1b proof-of-concept study...
2026-08-13 19:00
2344
Week's Top Stories
Most Reposted
Agoda Unveils Agoda Partner Portal as the Refreshed Platform's Role in Property Management Expands
[Picked up by 316 media titles]
2026-08-17 09:00
DayOne Launches Singapore's First Biological Data Center Prototype with Cortical Labs and NUS Medicine
[Picked up by 304 media titles]
2026-08-17 10:00
Intuitive Expands Manufacturing Footprint in Asia Pacific with New Facility in Penang, Malaysia
[Picked up by 291 media titles]
2026-08-17 14:19
Traveloka SEA Index Q2 2026: Southeast Asians Are Booking Longer Stays and the Region's Own Beaches Are Winning
[Picked up by 288 media titles]
2026-08-18 09:00
Miss World 2026 at Dragon Ocean Do Son: Elevating Vietnam's destination profile on the global stage
[Picked up by 283 media titles]
2026-08-19 17:43
Most Read
Agoda Unveils Agoda Partner Portal as the Refreshed Platform's Role in Property Management Expands
2026-08-17 09:00
18300
DayOne Launches Singapore's First Biological Data Center Prototype with Cortical Labs and NUS Medicine
2026-08-17 10:00
15229
H World Group Reports Strong Second-Quarter 2026 Performance and Announces New Shareholder Return Plan
2026-08-17 21:13
8564
